clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Bronchitis D001991 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Chlamydia Infections D002690 7 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Colitis D003092 69 associated lipids
Confusion D003221 4 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Cross Infection D003428 9 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cysts D003560 4 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatomycoses D003881 17 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Diphtheria D004165 2 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenitis D004382 4 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Dyspepsia D004415 5 associated lipids
Dyspnea D004417 10 associated lipids
Ecchymosis D004438 3 associated lipids
Empyema D004653 3 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Endometriosis D004715 29 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Ergotism D004881 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Exanthema D005076 11 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Foot Diseases D005534 4 associated lipids
Fractures, Open D005597 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Gastritis D005756 27 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Giardiasis D005873 3 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Hand Dermatoses D006229 5 associated lipids
Hearing Disorders D006311 10 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Heart Failure D006333 36 associated lipids
Hemolysis D006461 131 associated lipids
Hemophilia A D006467 10 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Hiatal D006551 3 associated lipids
HIV Seropositivity D006679 15 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hypoproteinemia D007019 1 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Iris Diseases D007499 2 associated lipids
Iritis D007500 2 associated lipids
Ischemia D007511 18 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Klebsiella Infections D007710 7 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Leprosy D007918 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Elliott RL et al. Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572890
Griesgraber G et al. Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. 1998 J. Med. Chem. pmid:9572891
Al-Sibai MB et al. Ocular penetration of oral clarithromycin in humans. 1998 J Ocul Pharmacol Ther pmid:9867340
Wallace RJ and Brown BA Catheter sepsis due to Mycobacterium chelonae. 1998 J. Clin. Microbiol. pmid:9867491
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Louw JA et al. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. 1998 Aliment. Pharmacol. Ther. pmid:9768531
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Abe M et al. A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. 1998 Respir Med pmid:9893782
Jarboe E et al. Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. 1998 Diagn. Microbiol. Infect. Dis. pmid:9572027
Treiber G et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. 1998 Helicobacter pmid:9546119
Suzuki J et al. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. 1998 Helicobacter pmid:9546120
Murata H et al. Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. 1998 Am. J. Gastroenterol. pmid:9820380
Sasa K et al. [Antineoplastic therapeutic effect of clarithromycin in rats]. 1998 Jpn J Antibiot pmid:9597492
Miyamoto N et al. [Test to set dosages for long-term administration of clarithromycin to treat chronic paranasal sinusitis]. 1998 Jpn J Antibiot pmid:9597498
Fujita K et al. [Neutrophil count and IL-8 level of nasal secretion of patients with chronic paranasal sinusitis and the effects of macrolide antibiotics]. 1998 Jpn J Antibiot pmid:9597505
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Williamson R et al. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. 1998 Scand. J. Gastroenterol. Suppl. pmid:9515751
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. 1998 Am. J. Gastroenterol. pmid:9517644
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Roussel G and Igual J Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. 1998 Int. J. Tuberc. Lung Dis. pmid:9626603
Nordt SP et al. Clarithromycin induced digoxin toxicity. 1998 J Accid Emerg Med pmid:9639187
Gray VS Syncopal episodes associated with cisapride and concurrent drugs. 1998 Ann Pharmacother pmid:9640482
Grove DI et al. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. 1998 Pathology pmid:9643503
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
Anzueto A et al. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. 1997 Sep-Oct Clin Ther pmid:9385486
Svoboda P et al. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. 1997 May-Jun Hepatogastroenterology pmid:9222709
Best LM et al. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. 1997 May-Jun Can. J. Gastroenterol. pmid:9218854
O'Brien B et al. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. 1997 May-Jun Can. J. Gastroenterol. pmid:9218858
al-Humayyd MS Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. 1997 Mar-Apr Chemotherapy pmid:9084915
Grunden JW and Fisher KA Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. 1997 Jul-Aug Ann Pharmacother pmid:9220046
Tartaglione T Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. 1997 Jul-Aug Clin Ther pmid:9377608
Mikasa K et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. 1997 Jul-Aug Chemotherapy pmid:9209786
Nawarskas JJ et al. Digoxin toxicity secondary to clarithromycin therapy. 1997 Jul-Aug Ann Pharmacother pmid:9220047
Dautzenberg B et al. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. 1997 Jan-Feb Infection pmid:9039532
Kearsley NL et al. Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. 1997 Apr-May Br J Clin Pract pmid:9293051
Irie Y et al. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. 1997 J. Antimicrob. Chemother. pmid:9301989
Stone GG et al. PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. 1997 J. Antimicrob. Chemother. pmid:9301991
López-Brea M et al. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. 1997 J. Antimicrob. Chemother. pmid:9301996
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Verhaegen J et al. Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae. 1997 Acta Clin Belg pmid:9204588
Kim MJ et al. Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. 1997 Gastroenterology pmid:9207259
Gotoh A et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. 1997 Microbiol. Immunol. pmid:9087962
Driscoll MS and Tyring SK Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. 1997 J. Am. Acad. Dermatol. pmid:9091495
Gui GP et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. 1997 J. Antimicrob. Chemother. pmid:9096189
Hoogkamp-Korstanje JA et al. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin. 1997 J. Antimicrob. Chemother. pmid:9096192
Fujii K et al. Multiple primary Mycobacterium avium infection of the skin. 1997 Int. J. Dermatol. pmid:9071619
Yanagihara K et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. 1997 Am. J. Respir. Crit. Care Med. pmid:9001333
Gan VN et al. Penetration of clarithromycin into middle ear fluid of children with acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9002099
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Pendland SL et al. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. 1997 J. Clin. Microbiol. pmid:9350781
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Ridgway GL et al. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. 1997 J. Antimicrob. Chemother. pmid:9484871
Martin SJ et al. In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. 1997 Diagn. Microbiol. Infect. Dis. pmid:9401809
Sander P et al. The role of ribosomal RNAs in macrolide resistance. 1997 Mol. Microbiol. pmid:9402018
Brancato R et al. Mycobacterium chelonae keratitis after excimer laser photorefractive keratectomy. 1997 Arch. Ophthalmol. pmid:9338681
Jingu K et al. [A case of fluminant Mycoplasma pneumonia and bronchiolitis managed by artificial respiration]. 1997 Nippon Naika Gakkai Zasshi pmid:9340346
Szántó D et al. [Could Helicobacter pylori cause reactive arthro-osteitis?]. 1997 Orv Hetil pmid:9340585
Yamamoto M et al. [The clinical study of clarithromycin for pulmonary Mycobacterium avium-intracellulare complex infection]. 1997 Kekkaku pmid:9038009
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Greco S et al. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin and other antibiotics. 1997 Ann Pharmacother pmid:9416400
Sugihara J et al. [Efficacy of clarithromycin on chronic paranasal sinusitis--a comparison between children and adult]. 1997 Jpn J Antibiot pmid:9597431
Hamada K et al. [Evaluation of antineoplastic effect of CAM (clarithromycin) in a mouse model inoculated with lung cancer cells]. 1997 Jpn J Antibiot pmid:9597434
Dautzenberg B Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease. 1997 Drugs pmid:9358194
Cohn DL Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. 1997 Drugs pmid:9358195
Tzivras M et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. 1997 Eur J Gastroenterol Hepatol pmid:9471024
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
McLaren A et al. The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. 1997 Helicobacter pmid:9432317
Bardhan KD et al. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. 1997 Helicobacter pmid:9432318
Takimoto T et al. The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. 1997 Helicobacter pmid:9432334
Moayyedi P Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? 1997 Ital J Gastroenterol Hepatol pmid:9513823
Pieramico O et al. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. 1997 Helicobacter pmid:9432335
Konishi T and Nakao M Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites. 1997 Microbiol. Immunol. pmid:9087959
García-de-Lomas J et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from pediatric carriers in Spain. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063666
Weiss I et al. Serotyping and susceptibility to macrolides and other antimicrobial drugs of Streptococcus pyogenes isolated from patients with invasive diseases in southern Israel. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063669
Bordet AL et al. [Mycobacterium chelonae cutaneous infection: efficacy of prolonged treatment by clarithromycin]. 1997 Ann Dermatol Venereol pmid:9686059
Thornsberry C et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. 1997 Diagn. Microbiol. Infect. Dis. pmid:9458982
Briant C et al. Pericarditis as a manifestation of Lyme disease. 1997 J Emerg Nurs pmid:9460386
Feldman C et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. 1997 Inflammation pmid:9429912
Lévy M et al. Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically. 1997 Gastrointest. Endosc. pmid:9351036
Laine L et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9354200
Rinaldi V et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. 1997 Aliment. Pharmacol. Ther. pmid:9354202
Breuer T et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. 1997 Aliment. Pharmacol. Ther. pmid:9354204
Wurzer H et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. 1997 Aliment. Pharmacol. Ther. pmid:9354205
Harris A H. pylori eradication by LAC. 1997 Aliment. Pharmacol. Ther. pmid:9354216
Barry AL et al. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9405952
Mitsuyama T et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. 1997 Int. Arch. Allergy Immunol. pmid:9338603
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Midolo PD et al. Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods. 1997 Pathology pmid:9423225
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Sekkarie MA Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. 1997 Am. J. Kidney Dis. pmid:9292575
Akaki T et al. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. 1997 Kekkaku pmid:9293712
Recker MW and Kier KL Potential interaction between clarithromycin and warfarin. 1997 Ann Pharmacother pmid:9296238
Laberge P and Martineau P Clarithromycin-induced digoxin intoxication. 1997 Ann Pharmacother pmid:9296239
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. 1997 Gut pmid:9301496